Clinical trial protocols become overly complex because teams copy and paste from previous studies, accumulating unnecessary data points and criteria. Merck advocates for "protocol lean design," which starts from the core research question and rigorously challenges every data collection point to reduce site and patient burden.

Unlike the unified US system, running a multi-country clinical trial in Europe is a bureaucratic nightmare. A single trial can require three slightly different protocols for Switzerland, the UK, and Spain, for example, creating significant delays, costs, and complexity for investigators.

A COVID-19 trial struggled for patients because its sign-up form had 400 questions; the only person who could edit the PHP file was a grad student. This illustrates how tiny, absurd operational inefficiencies, trapped in silos, can accumulate and severely hinder massive, capital-intensive research projects.

The industry's standard practice of selecting sites based on pre-existing relationships and convenience—the "easy button"—is a primary driver of failure. This leads to 80% of activated sites missing enrollment targets and 30% enrolling zero patients, a massive, systemic inefficiency that data-driven approaches can solve.

Sponsors often optimize financial processes for internal control, compliance, and budget governance. Research sites, however, prioritize clarity, predictability, and prompt payment. This fundamental disconnect in what's considered important is the root cause of administrative burden and erodes trust between partners.

A significant portion of biotech's high costs stems from its "artisanal" nature, where each company develops bespoke digital workflows and data structures. This inefficiency arises because startups are often structured for acquisition after a single clinical success, not for long-term, scalable operations.

The primary bottleneck in U.S. clinical trials is not the FDA's 30-day IND approval process, but the slow, expensive 'nuts and bolts' of site activation. This includes redundant budget negotiations, contract formats, and separate scientific and IRB reviews for the same protocol across multiple institutions.

Clinical trial sites are increasingly leveraging their power to demand protocol modernization from sponsors. Merck changed its internal processes to allow non-physician sub-investigators only after a site refused to participate without that flexibility. This shows that operational change can be driven from the ground up by partners, not just top-down by sponsors.

Using disconnected financial systems for modern, complex trials technically works but leads to crashes, slowness, and constant troubleshooting. This unsustainability directly risks study performance, site success, and patient engagement, making modernization a necessity, not a choice.